Loading
A phase 3 trial of Cediranib in Ovarian cancer, run by Medical Research Council, with a status the registry has not verified recently.
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer is a phase 3 interventional study registered as NCT00532194 by Medical Research Council, with 486 participants planned, started 2007-07 and due to reach its primary completion in 2013-04. Interventions recorded: cediranib. Conditions recorded: Ovarian Cancer.
Linked to the drug Cediranib because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares MRC Clinical Trials Unit at UCL and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.